Stanley Druckenmiller’s Acadia Pharmaceuticals ACAD Stock Holding History

Stanley Druckenmiller’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-74,400	Closed	-$1.78M	–	42
2023 Q2	$1.78M	Hold	74,400	–	–	0.06%	49
2023 Q1	$1.4M	Hold	74,400	–	–	0.06%	45
2022 Q4	$1.18M	Hold	74,400	–	–	0.06%	54
2022 Q3	$1.22M	Hold	74,400	–	–	0.07%	60
2022 Q2	$1.05M	Hold	74,400	–	–	0.08%	40
2022 Q1	$1.8M	Hold	74,400	–	–	0.08%	49
2021 Q4	$1.74M	Hold	74,400	–	–	0.06%	47
2021 Q3	$1.24M	Hold	74,400	–	–	0.04%	47
2021 Q2	$1.81M	Buy	+74,400	New	+$1.68M	0.05%	50

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Stanley Druckenmiller's ACAD Position: Q3 2023 in Review

Stanley Druckenmiller sold out of Acadia Pharmaceuticals (ACAD) in Q3 2023, closing a stake of 74,400 shares — an estimated $1.78M sold.

Stanley Druckenmiller first reported a position in ACAD in Q2 2021 and held it in 9 quarters. The position peaked at $1.81M in Q2 2021. 248 funds tracked by Wall St. Rank hold ACAD as of Q3 2023.

Stanley Druckenmiller reported no remaining Acadia Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
Stanley Druckenmiller sold 74,400 Acadia Pharmaceuticals shares in Q3 2023, an estimated $1.78M.
Stanley Druckenmiller first reported a position in Acadia Pharmaceuticals in Q2 2021 and held it in 9 quarters.
Stanley Druckenmiller's Acadia Pharmaceuticals position peaked at $1.81M in Q2 2021.
248 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2023.

Based on Duquesne Family Office's 13F filing for Q3 2023, filed 14 Nov 2023.